Disappointing Trial Outcomes for Heat Biologics’ (HTBX) Drug; Wall Street Surprised by Tilly’s’ (TLYS) Performance


Heat Biologics, Inc. (Nasdaq:HTBX) shares dropped more than 50% in after-hours trading Wednesday as the company said that researchers of a mid-stage trial evaluating its HS-410 (vesigenurtacel-L) alone or combined with Bacillus Calmette-Guérin – standard of care – reported that the vaccine did not perform better than placebo arms for recurrence-free survival at one year – the study’s primary endpoint – in patients with non-muscle invasive bladder cancer.

HTBX stock finished the regular session in negative territory by 3.69% (or -$0.11) at $2.87 with a total volume of 6.55M shares traded, representimg a large increase in activity versus its average volume (3m) of 1.49M shares

Heat Biologics, which focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases, has 23.88M shares outstanding and HTBX stock 52-week range is from $0.40 to $4.71 per share. At close on Wednesday, the biopharmaceutical company had a market capitalization of $68.55M



Shares of Tilly’s, Inc. (NYSE:TLYS) climbed over 14% to touch a new 52-week high in the extended session Wednesday after the specialty retailer company delivered stronger-than-expected quarterly profit and revenue numbers in its financial results.

For the third quarter fiscal 2016, Tilly’s posted net sales of $152.1 million, a 7.3% increase year over year, and net income of $6.4 million, or $0.22 per diluted share, versus a net income of $2.8 million, or $0.10 per diluted share in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of $0.11 earnings per share on revenues of $143.3 million for the period

According to its business outlook, Tilly’s expects fourth quarter 2016 earnings per diluted share to be between $0.15 and $0.20, versus $0.10 in the same period a year ago.

TLYS stock closed at $9.87, down $0.43 (or -4.17%) and 377,375 of its shares changed hands during the day.

Tilly’s, which retails casual apparel, footwear and accessories for young men, young women, boys and girls, has 12.48M shares outstanding, market capitalization (intraday) of $281.77M and TLYS stock one-year range is between $5.49 and $10.88 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/